| |  Online-Ressource |
|---|
| Verfasst von: | Kramer, Benedikt [VerfasserIn]  |
|---|
| | Hock, Clemens [VerfasserIn] |
|---|
| | Lammert, Anne [VerfasserIn] |
|---|
| | Walter, Beatrice [VerfasserIn] |
|---|
| | Birk, Richard [VerfasserIn] |
|---|
| | Hörmann, Karl [VerfasserIn] |
|---|
| | Aderhold, Marc Christoph [VerfasserIn] |
|---|
| Titel: | Impact of small molecules on β-catenin and E-cadherin expression in HPV16-positive and -negative squamous cell carcinomas |
|---|
| Verf.angabe: | Benedikt Kramer, Clemens Hock, Johannes David Schultz, Anne Lammert, Beatrice Kuhlin, Richard Birk, Karl Hörmann and Christoph Aderhold |
|---|
| E-Jahr: | 2017 |
|---|
| Jahr: | June 2017 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 13.11.2018 |
|---|
| Titel Quelle: | Enthalten in: Anticancer research |
|---|
| Ort Quelle: | Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |
|---|
| Jahr Quelle: | 2017 |
|---|
| Band/Heft Quelle: | 37(2017), 6, Seite 2845-2852 |
|---|
| ISSN Quelle: | 1791-7530 |
|---|
| Abstract: | Background: The validation of potential molecular targets in head and neck squamous cell carcinoma (SCC) is mandatory. β-Catenin and E-cadherin are crucial for cancer progression through epithelial-mesenchymal transition. We analyzed the effect of the tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on β-catenin and E-cadherin expression in SCC with respect to human papillomavirus (HPV) status. Materials and Methods: Expression of β-catenin and E-cadherin in cell lines UMSCC 11A, UMSCC 14C and CERV196 under the influence of tyrosine kinase inhibitors were analyzed by enzyme-linked immunosorbent assay. Results: All agents reduced β-catenin and E-cadherin expression of HPV16-negative cells. Increased E-cadherin expression was observed after treatment with gefitinib and dasatinib in HPV16-positive cells. Conclusion: All substances, nilotinib, dasatinib, erlotinib and gefitinib have a significant impact on β-catenin and E-cadherin expression in both HPV16-positive and HPV16-negative cells in vitro. Alterations of β-catenin and E-cadherin could provide novel insights for future targeted therapies of head and neck SCC. |
|---|
| DOI: | doi:10.21873/anticanres.11636 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.21873/anticanres.11636 |
|---|
| | Volltext: http://ar.iiarjournals.org/content/37/6/2845 |
|---|
| | DOI: https://doi.org/10.21873/anticanres.11636 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | dasatinib |
|---|
| | drug resistance |
|---|
| | E-cadherin |
|---|
| | erlotinib |
|---|
| | gefitinib |
|---|
| | head and neck squamous cell carcinoma |
|---|
| | HPV16 |
|---|
| | nilotinib |
|---|
| | β-Catenin |
|---|
| K10plus-PPN: | 1583649115 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Impact of small molecules on β-catenin and E-cadherin expression in HPV16-positive and -negative squamous cell carcinomas / Kramer, Benedikt [VerfasserIn]; June 2017 (Online-Ressource)
